I don't know about that bugs. I always detected a certain consistency in the quirkiness of both of those "personalities" that would be difficult to easily replicate. Not impossible, mind you, but unlikely in my view.
Well, off the top of my head, there's "thespamfromkohlrabi" and "backwardnapalm" to name a few, but I have them all on ignore, so they're a distant memory. I would question wasting time going after him, cause this is ALL HE EVER DOES. It's literally his life. What a sicko.
Funny that he hasn't even unleashed a salvo of down thumbs using all his alternate IDs. He is avoiding it like the plague. Too busy surfing in the dark, I would presume.
I have attempted to find the study that was done recently that demonstrated a positive effect of mecasermin rinfabate (iPlex) in combination with another compound on ALS in a mouse/rat model. It seems to have disappeared. Anyone have a link?
H- All that info on the various poster sessions is in the press release from Sept 3 posted on Insmed's website.
Sure enough, if you visit Cowen's web site, you'll find INSM listed among the companies covered by Ritu Baral, who covered INSM before her move from Canaccord Genuity.
$75/share is what ITMN got. But they have twice or more the outstanding shares of INSM. You should expect $150/share.
This, for the drug Esbriet (pirfenidone), which is expected to generate $1B in yearly revenue by 2019 for the treatment of idiopathic pulmonary fibrosis (IPF), an orphan disease. On February 28, 2011, the European Commission (EC) granted marketing authorization in all 28 EU member states. It is also available in Canada, Japan, South Korea, China, India, Argentina and Mexico, BUT NOT IN THE U.S., in spite of the drug receiving FDA Orphan Designation, Priority Review Designation, Fast Track Status and Breakthrough Designation. What happened? In one of two p3 trials completed in 2009, the primary endpoint was not met (p=0.501). For this failure, the company was set back by 5 years by the FDA. A third p3 trial was mandated and now they are resubmitting their NDA to the FDA in 3rd qtr 2014.
Does all this sound familiar? Orphan drug. Estimated revenue= $1B/yr. Relaxed standards abroad. BS FDA designations mean nothing in the US if you fail primary endpoint. If we follow the pattern, look for approval in the EU and possibly Japan. We shall see.
The following comments from the press release are encouraging and indicate that the potential for positive catalysts may not be that far down the road:
"We have already made extensive preparations for both trials, including design of the protocols and identification of CROs (clinical research organizations). Given the encouraging results of the previous trial, clinicians are keen to work with us to enroll patients quickly. We look forward to continuing to work with the FDA on the regulatory review and to sharing INTERIM DATA from these studies in a timely fashion."
Hmm....interim data on the short trial which ends in the first half of 2016 means that we will probably get the interim data in short order, probably in less than a year from now. What would happen to the stock price if more positive comments from patients emerge on the NTM forums? There could be a run-up in anticipation of confirmatory results.
Reminds me of the recent NYTimes crossword in which the theme quote was:" Is it just ME or are there other anagrams of EM? " The answer is obvious. It's not just you.
I can always tell when he has gone apoplectic by all the unread messages piling up at the bottom of the page. What stick got in his craw this time, the Sharoky news?
This stock is essentially no longer retail, until insti's want to distribute way down the road, so I wonder why we should even be concerned about or respond to a negative psychotic troll. This board belongs to him, he lives here for whatever reason and Yahoo allows that, so let him have it...I won't read it any more. It's called liberation. If you want to post your thoughts, move on over to InvestorVillage.
Well, isn't that convenient? Short it down in a news vacuum, build fear, cover and buy a long position. Then short it when it goes up, locking in a short term gain and going neutral. No risk while the short term gain matures into a lower taxed long term gain. Sit out the binary news while neutral. Cover when and if there is a sell the news event that is positive, going long after the coast is clear. Seems reasonable to me.
Here is the title of the phase 2 trial as seen on clinicaltrials.gov
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Shire
Information provided by (Responsible Party):
Part D of the phase 2 study with 120 subjects will be conducted at hospitals in Italy, Netherlands, Poland, Sweden and the United Kingdom and will be complete in March 2015. I'd say they had quite a bit of success in Parts A, B and C.